Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterised by inattention, hyperactivity, impulsivity and cognitive dysfunction (Agerbo *et al*., [@ref1]). The global lifetime prevalence of ADHD is estimated to be 7.2% (Thomas *et al*., [@ref37]). ADHD is significantly associated with impairments in daily life, daily functioning at school or work, and social and emotional development (Buitelaar and Medori, [@ref4]). Furthermore, it has implications for family stress and health care resource consumption (Dittmann *et al*., [@ref17]). In addition, the core symptoms of ADHD, including inattention, distractibility and impulsivity, probably account for the increased risk of unintentional injuries (Cairney, [@ref5]). ADHD is associated with an increased risk of accident and injury (Rowe *et al*., [@ref32]; Chang *et al*., [@ref6]; Chang *et al*., [@ref8]), leads to a shorter life expectancy, and those accidents or injuries are the most common cause of death in ADHD patients (Dalsgaard *et al*., [@ref16]; Chen *et al*., [@ref13]).

Burn injuries can be a devastating event, imposing a physical, psychological and economic burden on such patients and society (Chen *et al*., [@ref10]). Children with ADHD are at an increased risk of burn injury (Mangus *et al*., [@ref28]; Thomas *et al*., [@ref36]; Fritz and Butz, [@ref20]; Badger *et al*., [@ref3]; Ghanizadeh, [@ref21]). The most recent case--control study including 223 patients demonstrated that the prevalence of burn injury among children with ADHD (10.6%) was higher than that among the control group (2.0%) (Ghanizadeh, [@ref21]). A retrospective study by Badger *et al*. also reported that children with ADHD or ADD were more frequently involved in activities with a high risk of burn injury and more frequently experienced mental health difficulties (Badger *et al*., [@ref3]).

Pharmacotherapy is the first-line treatment for children with ADHD, and it can effectively reduce ADHD symptoms at all ages (Subcommittee on Attention-Deficit/Hyperactivity *et al*., [@ref39]). Robust evidence has been reported to support methylphenidate (MPH) as preferred first-choice medications for the short-term treatment of ADHD in children and adolescents (Cortese *et al*., [@ref14]). Studies have proposed that treatment with stimulants might reduce the risk of injuries in patients with ADHD (Dalsgaard *et al*., [@ref15]; Man *et al*., [@ref27]; Mikolajczyk *et al*., [@ref29]; Liang *et al*., [@ref25]). One population-based prospective cohort study reported that treatment with ADHD drugs reduced the risk of injuries and emergency ward visits (Dalsgaard *et al*., [@ref15]). No study has evaluated whether exposure to psychostimulant treatment mitigates the risk of burn injury or examined the effect of the duration of medication administration. We therefore explored the effect of the psychostimulant MPH on the risk of burn injury in patients with ADHD and whether the mitigating effects are related to the duration of exposure, by using a nationwide population-based dataset in Taiwan. We hypothesised that ADHD medication was linked to a lower risk of burn injury.

Materials and methods {#sec1}
=====================

Study design and participants {#sec1-1}
-----------------------------

In this retrospective cohort study, we used data from the Taiwan National Health Insurance Research Database (NHIRD) under the aegis of the National Health Research Institute, which includes data on outpatient, ambulatory and hospital inpatient care, as well as on dental services. Taiwan launched a single-payer National Health Insurance programme on 1 March 1995, covering the delivery of all health care services to 99.5% of the national population (Ng, [@ref30]). The NHIRD holds some important information, such as patients\' demographic data, the medical institution visited, diagnostic codes, the drugs prescribed, the date of any prescriptions given and any claimed medical expenses. The database has been used in many epidemiologic studies in Taiwan (Lee *et al*., [@ref24]; Chen *et al*., [@ref12]). Several validation studies have shown that the data set represents modest to high sensitivity and positive predictive values (Hsieh *et al*., [@ref22]).

The ADHD cohort was selected from NHIRD. It included individuals younger than 18 years by 31 December 2013. For ensuring the diagnosis of ADHD, we only recruited participants with ADHD who received at least one inpatient diagnosis of ADHD (International Classification of Disease, 9th revision \[ICD-9\] code: 314) or more than two outpatient diagnoses within 1 year between 1 January 1996 and 31 December 2011.

Outcomes {#sec1-2}
--------

The main outcome of this study was burn injury (ICD-9-CM codes: 940--949). Patients with a diagnosis of burn injury (Mangus *et al*., [@ref28]) before the diagnosis of ADHD were excluded. Patients with ADHD were followed up for the incidence of burn injury as an outcome, or until age 18, or to the end of 2013.

Assessment of other characteristics {#sec1-3}
-----------------------------------

Several covariates were selected, including sex, age, urbanisation level of residence and seizure (ICD-9 code: 345). Psychiatric comorbidity included intellectual disability (ICD-9 codes: 317--319), autism (ICD-9 code: 299), conduct disorder (ICD-9 code: 312), opposition defiant disorder (ICD-9-CM code: 313.81), anxiety (ICD-9 code: 300) and depression (ICD-9 codes: 296.2, 296.3, 300.4 and 311). Baseline medication use was identified based on a prescription of any benzodiazepine (ATC codes: N03AE, N05BA and N05CD), benzodiazepine-related drugs (ATC code: N05CF), antipsychotic (ATC code: N05A) or antidepressant (ATC code: N06A) 12 months prior to the burn injury diagnosis.

MPH (ATC code: N06BA04) has been the only stimulant approved for treating ADHD in Taiwan and is regarded as the first-line treatment for ADHD according to Taiwan\'s National Insurance. In 2017, atomoxetine (ATX), a non-stimulant, was also approved for ADHD treatment in Taiwan. However, compared with MPH, ATX has a much lower prescription rate (4% in all patients with ADHD) (Lee *et al*., [@ref23]). ATX is recommended only for cases where patients have insufficient treatment outcomes (i.e. inefficacy and intolerability) from MPH. Thus, it can be reasonably assumed that patients who received ATX have had prior MPH treatment exposure. Therefore, we included patients with only MPH exposure in this study. We investigated the treatment duration effect by examining MPH use in the ADHD cohort. The definition of treatment duration was the cumulative length of MPH exposure (days) within the follow-up period until end-points of burn injury, death or the end of the study. The ADHD population was divided into three subgroups based on the duration of MPH prescription: 0, \<90 and ≥90 days. This study was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital.

Statistical analysis {#sec1-4}
--------------------

All data management and statistical analyses were performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA) and R 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria). To describe the distribution of the study population, a *χ*^2^ test was used to compare the characteristics between the ADHD and control groups. The adjusted risk of burn injury between ADHD with and without MPH medication and the preventable fraction of MPH medication among individuals with ADHD was estimated using a Cox proportional hazards regression model. The results are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). We calculated the duration of medication use for each patient with ADHD and tested the cumulative effect on the burn incidence according to stratification into three groups, 0, \<90, ≥90 days, by adjusting for covariates in competing risk-adjusted Cox regression models (Allgulander and Fisher, [@ref2]). Age-stratified analysis was also conducted to examine the cumulative effect of MPH at three different age groups: (1) age \<6, (2) age between 6 and 12, and (3) age \>12 and \<18. Participants\' age is calculated by the difference between their birthdate and the end of follow-up (i.e. 31 December 2013) (Allgulander and Fisher, [@ref2]). To examine the immortal time bias, a sensitivity analysis using time-dependent Cox hazards regression analysis was performed. We also estimated the preventable fraction: the proportion of incidents of burn in patients with ADHD not taking MPH that could be prevented by MPH medication.

For within-patient comparisons, we used the self-controlled case series (SCCS) model, in which time was divided into periods similar to the stratified Cox regression model, with each patient as a separate stratum (i.e. the patient served as his or her own control). The risk estimated from the SCCS model indicates the risk of burn injury when individuals took MPH compared to the period when they did not take MPH. The SCCS model automatically adjusts for all time-invariant factors (e.g. sex) for the same patient before and during the follow-up. The effect period for MPH was set at 1--3 months based on previous studies (Chen *et al*., [@ref9]; Chang *et al*., [@ref7]). Thus, the effect period was split into three 1-month effect periods: 0--30, 31--60 and 61--90 days from the end of each treatment period. Finally, we combined the three effect periods into one to report the average pooled estimate of MPH use for burn injury. [Figure 1](#fig01){ref-type="fig"} is present to illustrate the SCCS study design in this cohort. The SCCS model was applied using the SCCS package in R (Farrington *et al*., [@ref18]). Furthermore, a moderation analysis based on the SCCS model was conducted to examine whether the neurodevelopment disorders (i.e. intellectual disability and autistic spectrum disorder) modify the effect of MPH on burn injury in children and adolescents with ADHD. Fig. 1.Overview of the self-controlled case series study design. The self-controlled case series study design was used in this study for within-patient comparisons to examine the effect of methylphenidate on traumatic brain injury in adolescent patients with ADHD. The effect period for methylphenidate is set at 1--3 months. Thus, the effect period was split into three 1-month effect periods: 0--30, 31--60 and 61--90 days at the end of each treatment period. Individual\'s time not within the treatment period would serve as a self-controlled period for self-comparison. Time point of cohort entry was defined as the date of age of onset of ADHD. The end of follow-up was 31 December 2013.

Results {#sec2}
=======

[Table 1](#tab01){ref-type="table"} shows the characteristics of children with ADHD stratified to three subgroups: 0 days (22 347 patients), \<90 days (17 766 patients) and ≥90 days (50 521 patients). The risk of burn injury was 6.7, 4.5 and 2.9% in the three groups, respectively (*p* \< 0.0001). The preventable fraction of MPH medication was 0.508, indicating that 50.8% (11 352 patients) incidence of burn injury could be prevented if they took MPH medication. Table 1.Characteristics of children with ADHD with and without MPH useVariablesFrequencyMPH = 0 day0--90 days≥90 days*N*%*N*%*N*%*N*%*p* valueTotal90 63422 34717 76650 521GenderFemale18 51220.4555024.8386321.7909918.0\<0.0001Male72 1229.616 79775.213 90378.341 42282.0Age0--520 37222.5915741.0301617.0819916.2\<0.00016--1162 88069.411 95153.512 73871.738 19175.612--1873828.112395.5201211.341318.2CovariatesSeizure40674.511755.37324.121604.3\<0.0001Intellectual disability4310.51610.7830.51870.4\<0.0001Autism86039.5304213.615238.640388.0\<0.0001Conduct disorder34523.87243.26413.620874.1\<0.0001Opposition defiant disorder51325.72801.37254.141278.2\<0.0001Anxiety18 52820.421159.5302517.013 38826.5\<0.0001Depression23682.63731.74592.615363.0\<0.0001Benzodiazepine use30453.46733.06153.517573.50.0039Z-drugs use1650.2220.1300.21130.20.0011Antipsychotics use53405.98493.88284.736637.3\<0.0001Antidepressants use27653.14051.84562.619043.8\<0.0001Urbanised level of residence1 (City)32 55735.9905840.5596233.617 53734.7\<0.0001243 11147.610 14245.4868548.924 28448.1310 24611.322039.9218912.3585411.64 (Villages)47205.29444.29305.228465.6Burn injury37424.114946.77924.514562.9\<0.0001

[Table 2](#tab02){ref-type="table"} shows the influences of the MPH cumulative effect on the burn risk among patients with ADHD and different age groups. For the whole sample, compared with patients with ADHD not taking MPH, those taking MPH for \<90 days had an adjusted HR of 0.70 for burn injury (CI 0.64--0.77) and those taking MPH for ≥90 days had an adjusted HR of 0.43 (95% CI 0.40--0.47). The results of the trend test were significant (*p* \< 0.01). In addition, age-stratified analyses revealed a similar pattern in different age groups and the adjusted HR ranged from 0.55 to 0.87 for those taking MPH for \<90 days and 0.32 to 0.55 for those taking MPH for ≥90 days, respectively. [Table 3](#tab03){ref-type="table"} shows the sensitivity analysis which confirmed the inverse association between MPH and risk of burn injury using the time-dependent model. Table 2.Cox proportional hazards model for burn injury in children with ADHD and age-stratified analysisMethylphenidate useUnadjusted analysisAdjusted analysis model[^a^](#tfn2_1){ref-type="table-fn"}HR95% CI*p* valueHR95% CI*p* valueWhole sample0 day (ref.)1.00----1.00----\<90 days0.650.60--0.71\<0.00010.700.64--0.77\<0.0001≥90 days0.390.37--0.42\<0.00010.430.40--0.47\<0.0001Age \< 60 day (ref.)1.00----1.00----\<90 days0.540.46--0.63\<0.00010.550.46--0.64\<0.0001≥90 days0.310.27--0.35\<0.00010.320.28--0.37\<0.00016 ≤ age \< 120 day (ref.)1.00----1.00----\<90 days0.880.78--0.990.02780.870.78--0.980.0213≥90 days0.530.48--0.59\<0.00010.540.48--0.60\<0.000112 ≤ age \< 180 day (ref.)1.00----1.00----\<90 days0.830.54--1.280.39830.840.55--1.310.4443≥90 days0.550.37--0.820.00380.550.37--0.830.0045[^2] Table 3.Time-dependent Cox proportional hazards model for burn injury in children with ADHDUnadjusted analysisAdjusted analysis model[^a^](#tfn3_1){ref-type="table-fn"}VariablesHR95% CI*p* valueHR95% CI*p* valueMethylphenidate0 DDD (ref.)1.00----1.00----\>0 day0.650.61--0.70\<0.00010.720.67--0.78\<0.0001[^3]

[Table 4](#tab04){ref-type="table"} presents the effect of MPH on burn injury within patients with ADHD, which was determined using the SCCS model. Within-patient comparisons revealed a significant reduction in the risk of burn injury in effect periods from 0 to 30 (HR 0.49, 95% CI 0.44--0.55), 30 to 60 (HR 0.46, 95% CI 0.40--0.54) and 60 to 90 days (HR 0.51, 95% CI 0.42--0.41). An average pooled estimate of these effect periods indicated an HR of 0.49 and 95% CI of 0.45--0.53. Furthermore, we found that the effect of MPH on burn injury was attenuated in participants with ADHD and intellectual disability (*p* = 0.002), but not in autistic spectrum disorder (*p* \> 0.05). The protective effect (RR) was decreased from 0.49 in participants with ADHD to 0.61 in participants with ADHD and intellectual disability. Table 4.Stratified Cox regression for self-controlled case series model of burn injury in children with ADHDVariablesAdjusted analysis model[^a^](#tfn4_1){ref-type="table-fn"}HR95% CI*p* valueEffect period of methylphenidate0--30 days0.49(0.44--0.55)\<0.000130--60 days0.46(0.40--0.54)\<0.000160--90 days0.51(0.42--0.61)\<0.00010--90 days0.49(0.45--0.53)\<0.0001[^4]

Discussion {#sec3}
==========

To our knowledge, this is the first nationwide population-based cohort study to investigate the effect of medication usage on the risk of burn injury in ADHD patients. Our study looked into the risk of burn injury specifically and added to the existing evidence that MPH treatment was associated with a lower risk of burn injury among ADHD children. We found a lower incidence of burn injury in patients with ADHD prescribed MPH in the whole sample and different age subgroups. In total, 50.8% incidence of burn injury among patients with ADHD not taking MPH could be prevented if they took MPH medication. The effect was more prominent with increased duration of MPH use: a 30% reduction in the risk of burn injury with \<90 days of MPH use was observed, and a 57% reduction in the risk of burn injury with ≥90 days of MPH use was noted. Similar reductions were replicated in age-stratified analysis and the time-dependent and SCCS design. These results suggest the robust effect of MPH use on burn injury in ADHD.

Research has indicated that ADHD patients have a higher risk for burn injury than non-ADHD controls (Fredriksen *et al*., [@ref19]). The potential explanations include impulsivity, attention-deficit-related carelessness, overlooking danger, impairment in executive function and motor coordination. This study found that ADHD patients prescribed MPH had a reduced likelihood of burn injury and prior studies have also demonstrated correlations between burn injury and MPH. One retrospective chart review examined children admitted to a burn care facility with respect to ADHD diagnosis or history of stimulant prescription and found that although a high percentage of these children (nearly 89%) had been prescribed stimulant medication, approximately 42% of them had not taken their usual dose of MPH on the day of the burn injury; they were injured by impulsive fire-play behaviour (Thomas *et al*., [@ref36]). In the present study, an average within-patient risk reduction of 51% was noted from comparing periods of time exposed to stimulant medication and unexposed periods. We expand on prior findings that MPH treatment plays a role in the reduced risk of burn injury in patients with ADHD. Several studies have suggested benefits on core symptoms and cognitive performance improvement after stimulant treatment (Fredriksen *et al*., [@ref19]; Setyawan *et al*., [@ref35]). Nevertheless, the exact mechanism of such stimulants underlying reduction of burn injury risk in children with ADHD requires further investigation.

We also investigated the cumulative effect of MPH (using the cumulative duration of MPH prescription) on the risk of burn injury in patients with ADHD and found that the burn injury risk reduction was linked to an increased MPH usage duration. Studies have identified attenuation in the risk of fracture, suicide and traumatic brain injury to be associated with the dosage effect of MPH treatment (Chen *et al*., [@ref11]; Liang *et al*., [@ref25]; Liao *et al*., [@ref26]). Long-term stimulant treatment normalises delayed brain development and yield to neuroadaptive and neurochemical change (Schweren *et al*., [@ref34]). Functional magnetic resonance imaging studies have also shown that exposure to psychostimulants may alter brain function connectivity and activity (van der Marel *et al*., [@ref38]). Our findings extend previous evidence and hold implications for clinical practice -- sufficient duration of MPH treatment may be protective against burn injury.

This nationwide population-based study has several strengths. First, the nationally representative sample was substantial and minimised selection bias. Second, patients with ADHD were identified through physician-based diagnoses. Third, all MPH prescriptions are recorded in the NHIRD, avoiding misclassification bias. Also, by excluding burn injuries prior to ADHD diagnosis, the reverse causal relationship between ADHD and burn injury was eliminated. Finally, we used different models to demonstrate the robust treatment effect of MPH on burn injury. The between-subject treatment effect was observed in the Cox proportional hazards models. We found a significant cumulative duration of treatment dose-related effect of MPH treatment on burn risk, whereas within-subject treatment effects were assessed using the SCCS model. Some studies have also used the within-subject methodology (i.e. SCCS or case-crossover study design) to examine the effect of MPH on unintentional injuries (Ruiz-Goikoetxea *et al*., [@ref33]); however, these studies suffered from the small sample size because their sample size merely ranged from 328 to 4934 (Ruiz-Goikoetxea *et al*., [@ref33]). As a result, they focused on any type of injury, and they were not able to examine some specific causes of injury. For example, in Raman *et al*.\'s study, they had 328 individuals with ADHD who experienced an incident medically attended injury event and received at least one prescription for stimulant medication, but only 1.2% (4/328) reported experiencing burn injury (Raman *et al*., [@ref31]). In our study, because of the enforcement rules of the National Health Insurance in Taiwan, citizens in Taiwan are required to enrol in this insurance programme, resulting in sufficient data for examining this issue. In terms of the SCCS, we revealed that the risk was significantly reduced during the possible effect period of MPH treatment (1--3 months after treatment initiation). In addition, the major advantage of the SCCS model was that indication bias and any time-invariant confounders would be automatically controlled because of self-comparison. Finally, the time-dependent Cox model was conducted to address immortal time bias, which refers to a period of follow-up duration, by design, the outcome cannot occur. All these models provided similar results, suggesting that our study provided robust estimates of the inverse effects of MPH treatment on burn risk in children with ADHD.

This study had several limitations. First, the accuracy of disease diagnoses for ADHD or burn injury has not been documented. Second, information on drug adherence was lacking. Third, we did not evaluate the therapeutic effect of non-pharmacological treatment because behavioural therapy and psychoeducation were not fully registered in the NHIRD. Finally, the lack of MPH use in some patients may be due to a worsening of symptoms, and we did not have information on the severity of ADHD.

In conclusion, MPH treatment was linked to a lower risk of burn injury in children with ADHD, and the effect was stronger with longer MPH use.
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